Encochleated Amphotericin B clinical trials
Also written MAT2203.
How each study uses Encochleated Amphotericin B is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Matinas BioPharma Nanotechnologies, Inc. (6)
Studies
Open first, then newest update. How each study uses Encochleated Amphotericin B is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)CompletedPhase 1/2Matinas BioPharma Nanotechnologies, Inc.NCT04031833Written as MAT2203
- Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3Status unknownPhase 3Matinas BioPharma Nanotechnologies, Inc.NCT05541107Written as MAT2203
- Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic LeukaemiaWithdrawnPhase 2Matinas BioPharma Nanotechnologies, Inc.NCT03187691Written as Oral Encochleated Amphotericin B (CAMB)
- Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal CandidiasisWithdrawnPhase 2Matinas BioPharma Nanotechnologies, Inc.NCT03167957Written as Oral Encochleated Amphotericin B (CAMB)
- Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal InfectionWithdrawnPhase 1/2Matinas BioPharma Nanotechnologies, Inc.NCT03196921Written as Encochleated Amphotericin B
- Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)CompletedPhase 2Matinas BioPharma Nanotechnologies, Inc.NCT02971007Written as Oral Encochleated Amphotericin B (CAMB)